A biotech company backed by Chinese conglomerate Fosun Group and private equity giant Warburg Pincus has begun one of the first mid-stage human trials of a drug discovered and designed by artificial intelligence.
Insilico Medicine, which was founded by Latvian-born scientist Alex Zhavoronkov, said it had dosed a patient in China with a novel therapy to treat the chronic lung disease idiopathic pulmonary fibrosis (IPF).
您已阅读13%（599字），剩余87%（4158字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。